Clinical observation on treatment of chronic atrophic gastritis with Huazhuo Jiedu Decoction and acupoint application
-
摘要: 目的：探讨化浊解毒方联合穴位贴敷治疗浊毒内蕴证慢性萎缩性胃炎患者的临床疗效及安全性。方法：征集120例慢性萎缩性胃炎浊毒内蕴证患者，随机分为药贴组（化浊解毒方联合穴位贴敷）和胃复春组（胃复春片），每组各60例。治疗90 d后，对比2组治疗前后中医证候积分、胃镜下黏膜征象积分、病理组织学积分的变化情况；比较2组患者治疗后的证候疗效、胃镜疗效、病理组织学疗效、综合疗效以及不良事件发生情况。结果：治疗结束后，2组各积分均较治疗前降低，且药贴组总积分低于胃复春组（P<0.05）；药贴组的中医证候积分、胃镜下黏膜征象积分、病理组织学积分、综合疗效优于胃复春组（P<0.05）；2组不良事件发生率比较差异无统计学意义（P>0.05）。结论：化浊解毒方联合穴位贴敷疗法治疗浊毒内蕴证慢性萎缩性胃炎可以迅速缓解患者的临床症状，还可在一定程度上延缓或逆转胃镜及病理表现，起效快，疗效显著，安全性高。Abstract: Objective: To explore the clinical efficacy and safety of Huazhuo Jiedu Decoction combined with acupoint application in the treatment of chronic atrophic gastritis with turbid toxin syndrome. Methods: One-hundred and twenty patients with chronic atrophic gastritis with turbid toxin syndrome were voluntarily recruited, and they were randomly divided into a patch group(Huazhuo Jiedu Decoction combined with acupoint application) and a Weifuchun group(Weifuchun tablets) 60 for example, after 90 days of treatment, compare the changes of TCM syndrome scores, mucosal signs scores under gastroscopy, and histopathology scores between the two groups before and after treatment; compare the efficacy of syndromes, gastroscopy, pathology, and comprehensiveness of the two groups after treatment efficacy and occurrence of adverse events. Results: After the treatment, the scores of the two groups were lower than those before the treatment, and the total score of the medicated patch group was lower than that of the Weifuchun group(P<0.05); the medicated patch group had better syndromes, gastroscopy, histopathology, and comprehensive curative effect Weifuchun group(P<0.05); there was no significant difference in the incidence of adverse events between the two groups(P>0.05). Conclusion: Huazhuo Jiedu Decoction combined with acupoint sticking therapy can quickly relieve the clinical symptoms of patients with chronic atrophic gastritis with internal accumulation of turbid toxins. It can also delay or reverse gastroscopy and pathological manifestations to a certain extent, with quick onset, significant curative effect and safety high.
-
-
[1] 中国中西医结合学会消化系统疾病专业委员会.慢性萎缩性胃炎中西医结合诊疗共识意见(2017年)[J].中国中西医结合消化杂志, 2018, 26(2):121-131.
[2] 中华医学会消化病学分会.中国慢性胃炎共识意见(2017年, 上海)[J].胃肠病中华消化杂志, 2017, 37(11):721-738.
[3] 杨楚琪, 崔言坤, 李冀.柴胡疏肝散加味治疗肝胃气滞证慢性萎缩性胃炎癌前病变的临床观察[J].中华中医药杂志, 2021, 36(1):580-583.
[4] 徐伟超, 赵润元, 李佃贵, 等.国医大师李佃贵诊治慢性萎缩性胃炎临床经验的数据挖掘[J].中华中医药杂志, 2019, 34(9):4350-4353.
[5] 王伟, 王永森, 曹志群, 等.芪莲舒痞膏穴位贴敷治疗慢性萎缩性胃炎癌前病变的临床疗效观察[J].时珍国医国药, 2018, 29(12):2953-2955.
[6] 中华中医药学会脾胃病分会.慢性萎缩性胃炎中医诊疗共识意见[J].中医杂志, 2010, 51(8):749-753.
[7] 郑筱萸.中药新药临床研究指导原则[M].北京:中国医药科技出版社, 2002:124-129.
[8] 中华医学会消化病学分会幽门螺杆菌和消化性溃疡学组, 全国幽门螺杆菌研究协作组.第五次全国幽门螺杆菌感染处理共识报告[J].胃肠病学, 2017, 22(6):346-360.
[9] 国家中医药管理局.中医病证诊断疗效标准[M].南京:南京大学出版社, 1994:9-9.
[10] 中华医学会病理分会消化病理学组筹备组.慢性胃炎及上皮性肿瘤胃黏膜活检病理诊断共识[J].中华病理学杂志, 2017, 46(5):289-290.
[11] 郑君.甘草总黄酮对慢性萎缩性胃炎大鼠胃黏膜保护作用及药理机制研究[D].广州:南方医科大学, 2014.
[12] 李佃贵.从浊毒理论的建立与应用谈中医学创新与发展[J].中医杂志, 2020, 61(22):1938-1940.
[13] 刘玉萍, 邱小玉, 刘烨, 等.茵陈的药理作用研究进展[J].中草药, 2019, 50(9):2235-2241.
[14] 李曼, 张露蓉.中药白花蛇舌草抗炎作用研究进展[J/OL].辽宁中医药大学学报:1-7[2021-07-22].
[15] 金顺琪, 张露蓉.半枝莲药理效应及临床应用研究进展[J/OL].辽宁中医药大学学报:1-10[2021-07-22].
[16] 程晓华, 马新换.桔梗科中药特性及化学成分和药理活性的研究进展[J].临床合理用药杂志, 2020, 13(6):175-177.
[17] 贺艳萍, 肖小芹, 邓桂明, 等.中药穴位贴敷作用机理研究概况[J].中国中医药信息杂志, 2017, 24(3):134-136.
[18] 周炜, 李玉潇, 张艺璇, 等.经络诊察取穴法针刺治疗慢性萎缩性胃炎疗效观察[J].中国针灸, 2020, 40(9):928-932.
-
计量
- 文章访问数: 467
- PDF下载数: 1003
- 施引文献: 0
下载: